Abbott Laboratories 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories filed an unaudited Form 10-Q for the quarter ended March 31, 2023. The company operates through four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices.
Financial Performance and Key Metrics
- Net sales: $9.747 billion, down 18.1% from $11.895 billion in the prior-year quarter. Sales excluding foreign exchange declined 14.8%.
- Net earnings: $1.318 billion, compared with $2.447 billion.
- Diluted earnings per share: $0.75, compared with $1.37.
- Operating earnings: $1.509 billion, compared with $2.912 billion.
- Gross profit margin: 50.5%, compared with 53.8%.
- Operating margin: Approximately 15.5%, compared with approximately 24.5%.
- Net margin: Approximately 13.5%, compared with approximately 20.6%.
- Operating cash flow: $1.143 billion, down from $2.065 billion.
- Capital expenditures: $380 million, compared with $321 million.
- Cash and cash equivalents: $9.161 billion at March 31, 2023, compared with $9.882 billion at December 31, 2022.
- Total debt: Approximately $16.9 billion, consisting of $2.285 billion of current debt and $14.615 billion of long-term debt.
- Liquidity: Working capital was $9.8 billion. Abbott reported $5.0 billion of available credit lines expiring in 2025 and investment-grade debt ratings of AA- from S&P and A1 from Moody’s.
- Shareholder returns: Abbott repurchased approximately 3.0 million shares for $300 million and declared a quarterly dividend of $0.51 per share, up 8.5% year over year.
Material Changes Versus the Prior Comparable Period
- COVID-19 testing normalization: COVID-19 testing-related sales fell to approximately $730 million from $3.3 billion. Excluding these sales, total revenue increased 4.9%, or 9.4% excluding both COVID-19 testing sales and foreign exchange.
- Diagnostics: Sales declined 48.9% overall and 47.1% excluding foreign exchange, primarily because of lower rapid and molecular COVID-19 testing demand. Segment operating earnings fell to $651 million from $2.564 billion.
- Medical Devices: Sales increased 8.5% overall and 12.4% excluding foreign exchange. Growth was led by Diabetes Care, Structural Heart, Heart Failure, and Neuromodulation. FreeStyle Libre sales increased 25.4% excluding foreign exchange to approximately $1.2 billion.
- Nutritional Products: Sales increased 3.8% overall and 7.7% excluding foreign exchange, benefiting from the nonrecurrence of the prior-year infant-formula recall impact.
- Established Pharmaceutical Products: Sales increased 3.7% overall and 11.1% excluding foreign exchange.
- Profitability: Gross margin declined because of lower COVID-19 test sales, foreign exchange, and higher manufacturing input costs, partly offset by margin improvement initiatives and the absence of 2022 recall costs.
- Cash generation: Operating cash flow decreased by $922 million, primarily because of lower operating earnings, partly offset by improved trade-receivable collections and lower cash taxes.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide a clear quantitative full-year earnings or revenue guidance figure.
- Management stated that future COVID-19 testing demand is unpredictable and that the extent of its effect on Abbott’s business and results remains uncertain.
- Abbott faces competition, pricing pressure, rebates, foreign-exchange exposure, government regulation, healthcare reimbursement changes, supply and manufacturing cost risks, and technological and product-development risks.
- Abbott recorded approximately $17 million of restructuring charges in the quarter; the related accrued balance was $184 million at March 31, 2023.
- Legal and environmental proceedings had an estimated possible loss range of approximately $25 million to $35 million, with an accrued balance of approximately $30 million. Management does not expect the ultimate disposition to materially adversely affect the company.
- Abbott expects recorded gross unrecognized tax benefits to decrease by approximately $75 million to $80 million over the next twelve months as tax matters are resolved.
- On April 27, 2023, after quarter-end, Abbott completed the approximately $850 million cash acquisition of Cardiovascular Systems, Inc., which provides atherectomy technology for peripheral and coronary artery disease.
- Remaining performance obligations were approximately $4.1 billion in Diagnostics and $450 million in Medical Devices; Abbott expects to recognize approximately 60% over the next 24 months.
Important Facts for Investors to Verify
- Whether the decline in COVID-19 testing revenue is offset by sustainable growth in Medical Devices, Nutritionals, and Established Pharmaceuticals.
- The durability of FreeStyle Libre growth and the contribution from recently approved Medical Devices products.
- The effect of foreign exchange, inflationary manufacturing costs, and margin-improvement initiatives on gross margin.
- Updated full-year guidance, if subsequently provided, and the post-acquisition financial impact of Cardiovascular Systems, Inc.
- Future operating cash flow after pension contributions, capital expenditures, dividends, share repurchases, and acquisition spending.
- Debt maturities, interest-rate exposure, and the remaining $2.134 billion authorized under the share-repurchase program.
- Developments in regulatory, litigation, environmental, tax, product-recall, and healthcare-reimbursement matters.